Citation Impact
Citing Papers
HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help
2003 StandoutScienceNobel
Chemokines and Their Receptors Are Key Players in the Orchestra That Regulates Wound Healing
2013
Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects
2006
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
2011
Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents
2005
Mechanisms of Thrombus Formation
2008 Standout
Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity
2017 StandoutNobel
Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases
2008 StandoutNobel
PET imaging of acute and chronic inflammation in living mice
2007
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
1997 StandoutNobel
Prospects for Cardiovascular Research
2001 StandoutNobel
Recent advances: Treatment of myocardial infarction
1998
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury
1997
High-resolution crystal structure of human protease-activated receptor 1
2012 StandoutNatureNobel
Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor
1997
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Exercise Standards for Testing and Training
2013 Standout
Radiopharmaceuticals for scintigraphic imaging of infection and inflammation
2001
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
2009
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
2007 Standout
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
2005
Neutrophils in the activation and regulation of innate and adaptive immunity
2011 Standout
Chemopreventive Agents
1998
Codon engineering for improved antibody expression in mammalian cells
2007
Platelet Activation and Atherothrombosis
2007 Standout
Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury
2006
Monocyte Chemoattractant Protein‐1 (CCL2) in Inflammatory Disease and Adaptive Immunity: Therapeutic Opportunities and Controversies
2003
Antiplatelet Drugs
2008
Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys
2006
Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients
1993 Standout
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
2009
Prevention of Venous Thromboembolism
2004 Standout
Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives
2009
Targeting proteinase-activated receptors: therapeutic potential and challenges
2012
Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?
1993
An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study)
2001
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Inflammatory caspases are innate immune receptors for intracellular LPS
2014 StandoutNature
Myocardial Reperfusion Injury
2007 Standout
Chemokines in the vascular inflammatory response of atherosclerosis
2009
Sterile inflammation: sensing and reacting to damage
2010 Standout
The inflammatory response in myocardial injury, repair, and remodelling
2014 Standout
A conserved structural motif for lipopolysaccharide recognition by procaryotic and eucaryotic proteins
2000
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
2001 Standout
Idiopathic pulmonary fibrosis
2011 Standout
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
The immune system and cardiac repair
2008
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
2000 Standout
Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients
1999
Thrombosis as an intravascular effector of innate immunity
2012 Standout
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
2011 StandoutNature
Platelet-Active Drugs
2001
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study
2002
The Many Roles of Chemokines and Chemokine Receptors in Inflammation
2006 Standout
High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential
1992
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis
2006
Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock
2003
Nanoparticulate carriers for the treatment of coronary restenosis.
2007
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice.
1997
Abciximab Facilitates the Rate and Extent of Thrombolysis
1999
Crystal Structure of Human BPI and Two Bound Phospholipids at 2.4 Angstrom Resolution
1997 Science
Toward a New Frontier in Myocardial Reperfusion Therapy
1998
Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.
1995
Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy
1995
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets
2006
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
Controlled/living radical polymerization: Features, developments, and perspectives
2007 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Chemokines
2004
Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields
2014 Standout
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
1999
Targeting inflammatory pathways in myocardial infarction
2013
Wound Healing: A Cellular Perspective
2018 Standout
Ischemic Cell Death in Brain Neurons
1999 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Coronary Plaque Disruption
1995 Standout
Lipopolysaccharide Endotoxins
2002 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
High Mobility Group Box 1 Protein Binding to Lipopolysaccharide Facilitates Transfer of Lipopolysaccharide to CD14 and Enhances Lipopolysaccharide-Mediated TNF-α Production in Human Monocytes
2008
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Phylogenetic Perspectives in Innate Immunity
1999 StandoutScienceNobel
In Situ Preparation of Protein−“Smart” Polymer Conjugates with Retention of Bioactivity
2005
Imaging of vascular injury with 99mTc-labeled monoclonal antiplatelet antibody S12. Preliminary experience in human percutaneous transluminal angioplasty.
1992
Protease-Activated Receptors: Contribution to Physiology and Disease
2004
Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response
2004
Physiology of Microglia
2011 Standout
Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
2001
Works of Mark Nedelman being referenced
Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates
2003
Enhanced kidney clearance with an ester-linked 99mTc-radiolabeled antibody Fab'-chelator conjugate
1990
Detection of acute inflammation with 111In-Labeled nonspecific polyclonal IgG
1988
Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates
2002
Lipopolysaccharide (LPS) Neutralizing Peptides Reveal a Lipid A Binding Site of LPS Binding Protein
1995
Abciximab Pharmacodynamics Are Unaffected by Antecedent Therapy with Other GPIIb/IIIa Antagonists in Non-Human Primates
2002
Protease Activity in a Hapten-Induced Model of Ulcerative Colitis in Rats
1997
A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion
1995
Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins
1995
Evaluation of the monoclonal antibody and the use of technetium-99m-labeled Fab′ for the detection of pan adenocarcinoma
1991
An instant kit method for labeling antimyosin Fab' with technetium-99m: evaluation in an experimental myocardial infarct model.
1992
Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab')2 Fragment
1994
Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. II. Adjunctive Therapy with r-Hirudin
1994
In vivo imaging of acute arterial thrombi with technetium-99m anti-platelet monoclonal antibody
1990
Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation.
1990
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
1993
Specific and nonspecific imaging of localized Fisher immunotype 1 Pseudomonas aeruginosa infection with radiolabeled monoclonal antibody.
1988
Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab')2 Fragment
1994
Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates
2002
Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. II. Adjunctive Therapy with r-Hirudin
1994